

# K24 GUIDE FOR REVIEWERS

## Midcareer Investigator Award in Patient Oriented Research

### EXECUTIVE SUMMARY

Midcareer Investigator Award in Patient-Oriented Research (K24)

- Supported by NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NIMH, NINDS, NINR, NCCAM, and ODS
- Provides support for clinician investigators to allow them protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty

Visit parent FOA at <http://grants2.nih.gov/grants/guide/pa-files/PA-09-037.html>.

### INSTRUCTIONS FOR WRITTEN CRITIQUE AND PRELIMINARY SCORES

The mission of the NIH is to support science in pursuit of knowledge about the biology and behavior of living systems and to apply that knowledge to extend healthy life and reduce the burdens of illness and disability. As part of this mission, applications submitted to the NIH for grants or cooperative agreements to support biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

The overall goal of NIH-supported research career development programs is to help ensure that a diverse pool of highly trained scientists are available in adequate numbers and in appropriate research areas to address the Nation's biomedical, behavioral, and clinical research needs.

The Scientific Review Officer (SRO), and in particular the funding opportunity announcement (FOA) for each specific career development award, provide additional guidance for each core and additional review criterion. **Reviewers must become fully familiar with the detailed review criteria provided in each FOA before assessing any K award application in response to that announcement.**

#### Written Critiques

- The format of the critiques should follow the structured template provided for each mechanism, which can be downloaded from the Internet Assisted Review (IAR) site and found on the CD.
- Each core criterion and additional review criteria are represented in the reviewer template and should be commented on, listing the strengths and weaknesses of each in a bulleted form.
- The goal is to provide the maximum and most pertinent information in a concise manner.

- After considering all of the review criteria, briefly summarize the strengths and weaknesses of the application in the Overall Impact section of the template.
- Assigned reviewers must upload critiques before entering an overall impact/priority score.
- Criterion scores should be entered in IAR before the review meeting.
- Assigned reviewers may submit criterion scores only after their critiques have been uploaded. At the SRO's discretion, discussants who are assigned to the application and SRG members who are not assigned to the application may submit criterion scores without critiques.
- The criterion scores may be changed during FINAL SCORING on your electronic or paper Voter/Scoring Sheet, or following the review meeting during the EDIT phase.
- Please do not write your criterion scores on the critique template.

### **Preliminary Scores**

- Each core review criterion should be given a score using the nine-point rating scale in accordance with the new Enhanced Peer Review Criteria.
- The criterion scores for the applications should be entered in the meeting Internet Assisted Review (IAR) site in NIH Commons before the review meeting using the same page that is used for submitting the preliminary impact/priority score and critique.
- The criterion scores may be changed following the review meeting during the EDIT phase.
- In the READ phase of the meeting reviewers may submit their scores and critiques, but may not edit them. Core criterion scores can be submitted only after your critique had been uploaded into IAR.
- The criterion scores will appear in the summary statement as part of your critique.

### **Core Review Criteria**

Reviewers are asked to consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. These individual criterion scores are considered part of your critique and will not be discussed at the review meeting. They may be changed in the EDIT phase in IAR.

#### ***Candidate***

- Is there evidence of ongoing high quality patient-oriented research, and what is the relationship of that research to this K24 proposal?
- Is there evidence of the candidate's capabilities and commitment to serve as a mentor for new clinical investigators in the conduct of patient-oriented research?
- Does the application demonstrate that the proposed program and protected time will relieve the candidate from non-research patient care and administrative duties

and allow him/her to devote additional time and to augment his/her capabilities in patient-oriented research?

- Does the application demonstrate a record of independent peer-reviewed support for patient-oriented research that is likely to continue during the K24 award?

### ***Plan to Provide Mentoring***

- Are the plans to provide mentoring or supervising new clinical investigators in patient oriented research adequate?
- Are plans to integrate appropriate clinical research curricula, such as those offered by available K30 programs at the institution, into the mentoring plans adequate?
- Is an appropriate level of effort proposed for the mentoring component?

### ***Research Plan***

- Is the research plan an appropriate vehicle for demonstrating and developing the prospective mentee's skills and capabilities in patient-oriented research?
- Are the scientific and technical plans of the proposed research of merit?
- Is the proposed research relevant to the candidate's career objectives?
- Are adequate resources available to conduct the research program? This includes adequacy of plans for continued support of the research during the funding period of the grant.

### ***Consultant(s), Collaborator(s):***

- Is there adequate information provided that clearly documents expertise in the proposed area(s) of consulting/collaboration?

### ***Environment and Institutional Commitment to the Candidate***

- Is the level of the applicant institution's commitment to the scientific development of the candidate appropriate?
- Is the level of assurance from the institution that they intend the candidate to be an integral part of its patient-oriented research program adequate?
- Are the research facilities, resources and appropriate educational opportunities available to the candidate appropriate and adequate?
- Are the size and quality of the pool of clinician investigators to be mentored by the PI/PD adequate?
- Are the quality and relevance of the environment for continuing the scientific and professional development of the candidate and for others pursuing patient-oriented research appropriate and adequate?
- Is the commitment from the sponsoring institution to provide adequate protected time for the candidate to conduct the research and mentoring program adequate?

- Is the level of commitment of the candidate's institution to the career development in patient-oriented research of new clinical investigators mentored by the candidate adequate?

## **Additional Review Criteria**

As applicable for the project proposed, reviewers are asked to consider the following additional items in the determination of scientific and technical merit, but not to give separate scores for these items.

### ***Training in the Responsible Conduct of Research***

Does the application include appropriate and adequate documentation in prior instruction, or plans for training in the responsible conduct of research?

### ***Protections for Human Subjects***

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46 (as described in [Human Subjects Protection and Inclusion](#)), reviewers are asked to evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. If all of the criteria are adequately addressed, and there are no concerns, write "Acceptable Risks and/or Adequate Protections." A brief explanation is advisable. If one or more criteria are inadequately addressed, write, "Unacceptable Risks and/or Inadequate Protections" and document the actual or potential issues that create the human subjects concern. Also, if a clinical trial is proposed, evaluate the Data and Safety Monitoring Plan. (If the plan is absent, notify the SRO immediately to determine if the application should be withdrawn.) Indicate if the plan is "Acceptable" or "Unacceptable", and, if unacceptable, explain why it is unacceptable.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt, evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. If the claimed exemption is not justified, indicate "Unacceptable", and, if unacceptable, explain why it is unacceptable.

For additional information to assist you in making these determinations, please refer to [http://grants.nih.gov/grants/peer/guidelines\\_general/Human\\_Subjects\\_Protection\\_and\\_Inclusion.pdf](http://grants.nih.gov/grants/peer/guidelines_general/Human_Subjects_Protection_and_Inclusion.pdf) and [http://grants.nih.gov/grants/peer/guidelines\\_general/Human\\_Subjects\\_Worksheet.pdf](http://grants.nih.gov/grants/peer/guidelines_general/Human_Subjects_Worksheet.pdf).

### ***Inclusion of Women, Minorities and Children***

When the proposed project involves clinical research, reviewers are asked to evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children.

Public Law 103-43 requires that women and minorities must be included in all NIH-supported clinical research projects involving human subjects unless a clear and compelling rationale establishes that inclusion is inappropriate with respect to the health of the subjects or the

purpose of the research. NIH requires that children (individuals under the age of 21) of all ages be involved in all human subjects research supported by the NIH unless there are scientific or ethical reasons for excluding them. Each project involving human subjects must be assigned a code using the categories "1" to "5" below. Category 5 for minority representation in the project means that only foreign subjects are in the study population (no U.S. subjects). If the study uses both then use codes 1 thru 4. Examine whether the minority and gender characteristics of the sample are scientifically acceptable, consistent with the aims of the project, and comply with NIH policy. For each category, determine if the proposed subject recruitment targets are "A" (acceptable) or "U" (unacceptable). If you rate the sample as "U", consider this feature a weakness in the research design and reflect it in the overall score. Explain the reasons for the recommended codes; this is particularly critical for any item coded "U".

*NOTE: To the degree that acceptability or unacceptability affects the investigator's approach to the proposed research, such comments should appear under "Approach" in the five major review criteria above, and should be factored into the score as appropriate.*

For additional information to assist you in making these determinations, please refer to [http://grants.nih.gov/grants/peer/guidelines\\_general/Human\\_Subjects\\_Protection\\_and\\_Inclusion.pdf](http://grants.nih.gov/grants/peer/guidelines_general/Human_Subjects_Protection_and_Inclusion.pdf) and [http://grants.nih.gov/grants/peer/guidelines\\_general/Human\\_Subjects\\_Worksheet.pdf](http://grants.nih.gov/grants/peer/guidelines_general/Human_Subjects_Worksheet.pdf).

<b><u>Gender Inclusion Code</u></b>	<b><u>Minority Inclusion Code</u></b>	<b><u>Children Inclusion Code</u></b>
<b>G1</b> = Both genders	<b>M1</b> = Minority and nonminority	<b>C1</b> = Children and adults
<b>G2</b> = Only women	<b>M2</b> = Only minority	<b>C2</b> = Only children
<b>G3</b> = Only men	<b>M3</b> = Only nonminority	<b>C3</b> = No children included
<b>G4</b> = Gender composition unknown	<b>M4</b> = Minority composition unknown	<b>C4</b> = Representation of children unknown
	<b>M5</b> = Only foreign subjects	

### ***Vertebrate Animals***

Reviewers are asked to evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia.

For additional information to assist you in determining if the Vertebrate Animals section is "Acceptable" or "Unacceptable", please refer to: <http://grants.nih.gov/grants/olaw/VASchecklist.pdf>.

### ***Biohazards***

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

## ***Resubmission Applications***

When reviewing a Resubmission application (formerly called an amended application), please evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

## ***Renewal Applications***

- Has there been adequate progress in achieving the K24-supported career, research and mentoring objectives of the previous award period?
- Is the justification provided for an additional 3 to 5 years of support adequate? (This requires that the recipient continue to have independent peer-reviewed patient-oriented research support at the time of submission of the renewal application; and documentation of a continuing need for protected time to expand the POR program and the mentoring activities supported during the prior funding period of the award).
- Does the PD/PI adequately demonstrate the continuing need for protected time to expand his/her research and mentoring program?
- *Is there evidence of the PD/PI's continuing leadership in patient-oriented research through, for example, being principal investigator on new independent peer-reviewed research grants and providing high quality mentorship?*

## **Overall Impact**

Reviewers will provide an overall impact critique to reflect their assessment of the likelihood for candidate to maintain a strong research program, taking into consideration all of the criteria above (as appropriate for the application) in determining the overall impact/priority score. Your critique should indicate the most significant strengths and weaknesses.

## **Additional Review Considerations**

As applicable for the project proposed, reviewers will address each of the following items, but will not give scores for these items and should not consider them in providing an overall impact score.

### ***Budget and Period Support***

Is the proposed budget and period of support appropriate in relation to the proposed research and the career development needs of the candidate?

### ***Select Agents***

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s). Select agent information is available via [http://grants.nih.gov/grants/policy/select\\_agent/](http://grants.nih.gov/grants/policy/select_agent/).

## ***Resource Sharing Plans***

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable:

### ***1) Sharing Model Organisms***

(<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-042.html>). All NIH grant applications are expected to include a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. Unlike the NIH Data Sharing Policy, the submission of a model organism sharing plan is NOT subject to a cost threshold of \$500,000 or more in direct costs in any one year, and is expected to be included in all applications where the development of model organisms is anticipated.

### ***2) Genome Wide Association Studies***

(<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-013.html>). Applications and proposals that include GWAS, regardless of the requested costs, are expected to include as part of the Research Plan either a plan for submission of GWAS data to the NIH designated data repository or an appropriate explanation for why submission to the repository will not be possible.

## ***Additional Comments to the Applicant***

Reviewers may provide guidance to the applicant or recommend against resubmission without fundamental revision.